Review on Adverse effects or side effects of Remdisivir

Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil
{"title":"Review on Adverse effects or side effects of Remdisivir","authors":"Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil","doi":"10.52711/2321-5836.2021.00030","DOIUrl":null,"url":null,"abstract":"In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population. But the remdesivir is also harmful for the people because of it can have some side effects such as mentioned in the following information. There are so many type of disease started form the treatment of COVID-19 with the Remdesivir that also mentioned in the following review paper.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacology and Pharmacodynamics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/2321-5836.2021.00030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population. But the remdesivir is also harmful for the people because of it can have some side effects such as mentioned in the following information. There are so many type of disease started form the treatment of COVID-19 with the Remdesivir that also mentioned in the following review paper.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
瑞地西韦的不良反应或副作用综述
2020年3月,世界卫生组织宣布SARS-CoV-2蔓延为全球大流行。迄今为止,2019冠状病毒病(COVID-19)已蔓延到200多个国家,导致160多万例病例和9.9万多人死亡。鉴于目前既没有针对COVID-19的疫苗,也没有经过验证的治疗方法,目前迫切需要有效的药物治疗。为了解决在全球大流行期间有效治疗SARS-CoV-2的需求,对静脉注射(IV)瑞德西韦进行了系统评价。瑞德西韦是一种最初用于治疗埃博拉病毒病的抗病毒前药,已显示出对冠状病毒家族的广谱活性。最近的一份病例报告称,一名COVID-19患者使用瑞德西韦后临床症状有所改善。在对18个临床试验注册中心和3个大型科学数据库进行系统搜索后,我们确定了86个潜在的符合条件的项目。删除重复研究(n = 21)后,由两位作者独立审查符合条件的研究。第一轮筛选后,评分间一致性为98.5% (κ = 0.925)。在第二轮全文筛选后,评分者之间的一致性为100%。共纳入7项正在进行和正在招募的瑞德西韦(100-200毫克,静脉注射[IV])临床试验。我们确定了以下主要结局:患者出院(n = 2);到临床状态改善时间(n = 2);改善氧饱和度(n = 2);体温恢复正常(n = 2);和临床状态(n = 1)。所有确定的研究的次要结局包括不良事件的记录。第三阶段试验预计将于2020年4月至2023年完成。因此,尽管有来自体外和体内研究的支持性数据,但在人群中,静脉注射瑞德西韦治疗COVID-19的临床有效性和潜在副作用仍未完全确定。但是瑞德西韦对人也是有害的,因为它可能有一些副作用,比如下面的信息中提到的。有很多类型的疾病开始于用Remdesivir治疗COVID-19,这也在下面的综述文章中提到。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Facing the Challenge: Hormonal hurdles, Olfaction Obstacles in Kallmann Syndrome A Comprehensive Guide to Paget’s Disease of Bone A Review on Rett Syndrome: A Debilitating Neurodevelopmental Disorder Lumpy Skin Disease, an Emerging Transboundary Viral Disease in Animal’s: A Review Wolfram Syndrome: A Rare Genetic disorder affecting Multiple Organ Systems
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1